Skip to main content

Evolocumab is second PCSK9 inhibitor approved to lower LDL in high-risk patients

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
Evolocumab is second PCSK9 inhibitor approved to lower LDL in high-risk patients

User login

Username

Password

Reset your password

Type	Lead	score